CYP3A

Cytochrome P450, family 3, subfamily A, also known as CYP3A, is a human gene.cite web | title = Entrez Gene: CYP3A cytochrome P450, family 3, subfamily A| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1574| accessdate = ]

The CYP3A locus includes all the known members of the 3A subfamily of the cytochrome P450 superfamily of genes. These genes encode monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The CYP3A cluster consists of four genes:
* CYP3A4
* CYP3A5,
* CYP3A7, and
* CYP3A43. The region also contains two pseudogenes:
* and
*, as well as several extra exons which may or may not be included in transcripts produced from this region. Previously another CYP3A member, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4.cite web | title = Entrez Gene: CYP3A cytochrome P450, family 3, subfamily A| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1574| accessdate = ]

References

Further reading

PBB_Further_reading
citations =
*cite journal | author=Smith G, Stubbins MJ, Harries LW, Wolf CR |title=Molecular genetics of the human cytochrome P450 monooxygenase superfamily. |journal=Xenobiotica |volume=28 |issue= 12 |pages= 1129–65 |year= 1999 |pmid= 9890157 |doi=
*cite journal | author=Lamba JK, Lin YS, Schuetz EG, Thummel KE |title=Genetic contribution to variable human CYP3A-mediated metabolism. |journal=Adv. Drug Deliv. Rev. |volume=54 |issue= 10 |pages= 1271–94 |year= 2003 |pmid= 12406645 |doi=
*cite journal | author=Finta C, Zaphiropoulos PG |title=The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. |journal=Gene |volume=260 |issue= 1-2 |pages= 13–23 |year= 2001 |pmid= 11137287 |doi=
*cite journal | author=Gellner K, Eiselt R, Hustert E, "et al." |title=Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. |journal=Pharmacogenetics |volume=11 |issue= 2 |pages= 111–21 |year= 2001 |pmid= 11266076 |doi=
*cite journal | author=Miyazawa M, Shindo M, Shimada T |title=Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes. |journal=Xenobiotica |volume=31 |issue= 10 |pages= 713–23 |year= 2002 |pmid= 11695850 |doi=
*cite journal | author=Reid JM, Kuffel MJ, Ruben SL, "et al." |title=Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. |journal=Clin. Cancer Res. |volume=8 |issue= 9 |pages= 2952–62 |year= 2002 |pmid= 12231541 |doi=
*cite journal | author=Martínez C, García-Martín E, Pizarro RM, "et al." |title=Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. |journal=Br. J. Cancer |volume=87 |issue= 6 |pages= 681–6 |year= 2002 |pmid= 12237780 |doi= 10.1038/sj.bjc.6600494
*cite journal | author=Dowling TC, Briglia AE, Fink JC, "et al." |title=Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. |journal=Clin. Pharmacol. Ther. |volume=73 |issue= 5 |pages= 427–34 |year= 2003 |pmid= 12732843 |doi=
*cite journal | author=Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD |title=Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. |journal=Drug Metab. Dispos. |volume=32 |issue= 3 |pages= 359–63 |year= 2004 |pmid= 14977871 |doi= 10.1124/dmd.32.3.359
*cite journal | author=Somogyi AA, Menelaou A, Fullston SV |title=CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. |journal=Xenobiotica |volume=34 |issue= 10 |pages= 875–87 |year= 2005 |pmid= 15764408 |doi= 10.1080/00498250400008371
*cite journal | author=Thompson EE, Kuttab-Boulos H, Yang L, "et al." |title=Sequence diversity and haplotype structure at the human CYP3A cluster. |journal=Pharmacogenomics J. |volume=6 |issue= 2 |pages= 105–14 |year= 2006 |pmid= 16314882 |doi= 10.1038/sj.tpj.6500347
*cite journal | author=Bochud M, Eap CB, Elston RC, "et al." |title=Association of CYP3A5 genotypes with blood pressure and renal function in African families. |journal=J. Hypertens. |volume=24 |issue= 5 |pages= 923–9 |year= 2006 |pmid= 16612255 |doi= 10.1097/01.hjh.0000222763.84605.4a
*cite journal | author=Cheung CY, Op den Buijsch RA, Wong KM, "et al." |title=Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. |journal=Pharmacogenomics |volume=7 |issue= 4 |pages= 563–74 |year= 2006 |pmid= 16753004 |doi= 10.2217/14622416.7.4.563
*cite journal | author=Rais N, Chawla YK, Kohli KK |title=CYP3A phenotypes and genotypes in North Indians. |journal=Eur. J. Clin. Pharmacol. |volume=62 |issue= 6 |pages= 417–22 |year= 2007 |pmid= 16758258 |doi= 10.1007/s00228-006-0105-3
*cite journal | author=Kirby B, Kharasch ED, Thummel KT, "et al." |title=Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. |journal=Journal of clinical pharmacology |volume=46 |issue= 11 |pages= 1313–9 |year= 2007 |pmid= 17050796 |doi= 10.1177/0091270006292625
*cite journal | author=He P, Court MH, Greenblatt DJ, von Moltke LL |title=Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. |journal=Journal of clinical pharmacology |volume=46 |issue= 11 |pages= 1356–69 |year= 2007 |pmid= 17050801 |doi= 10.1177/0091270006292125
*cite journal | author=Watanabe A, Nakamura K, Okudaira N, "et al." |title=Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. |journal=Drug Metab. Dispos. |volume=35 |issue= 7 |pages= 1232–8 |year= 2007 |pmid= 17392390 |doi= 10.1124/dmd.107.015016
*cite journal | author=Kharasch ED, Walker A, Isoherranen N, "et al." |title=Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. |journal=Clin. Pharmacol. Ther. |volume=82 |issue= 4 |pages= 410–26 |year= 2007 |pmid= 17554244 |doi= 10.1038/sj.clpt.6100237

PBB_Controls
update_page = yes
require_manual_inspection = no
update_protein_box = yes
update_summary = no
update_citations = yes